Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Page Path
HOME > Browse Articles
Search
Sunmi Jo 1 Article
Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
Sunmi Jo, Yunseon Choi, Sung-Kwang Park, Jin-Young Kim, Hyun Jung Kim, Yun-Han Lee, Won Yong Oh, Heunglae Cho, Ki Jung Ahn
Ann Coloproctol. 2016;32(2):66-72.   Published online April 30, 2016
DOI: https://doi.org/10.3393/ac.2016.32.2.66
  • 4,276 View
  • 36 Download
  • 8 Web of Science
  • 7 Citations
AbstractAbstract PDF
Purpose

This study aimed to evaluate the effects of radiotherapy (RT) on progression-free survival (PFS) for patients with recurrent colorectal cancer.

Methods

We reviewed the records of 22 patients with recurrent colorectal cancer treated with RT between 2008 and 2014. The median radiation dose for recurrent disease was 57.6 Gy (range, 45–75.6 Gy). Patients were divided into 2 groups according to the type of RT: patients underwent RT without previous history of irradiation (n = 14) and those treated with secondary RT (reirradiation: n = 8) at the time of recurrence.

Results

The median follow-up period was 24.9 months (range, 4.5–66.6 months). Progression was observed in 14 patients (including 8 with loco-regional failure and 9 with distant metastases). Distant metastases were related to the RT dose (<70 Gy, P = 0.031). The 2-year loco-regional control (LRC), PFS, and overall survival (OS) rates were 74.6%, 45.1%, and 82.0%, respectively. The LRC rate was not different between the patients treated with RT for the first time and those treated with reirradiation (P = 0.101, 2-year LRC 79.5% vs. 41.7%). However, reirradiation was related to poor PFS (P = 0.022) and OS (P = 0.002). An escalated RT dose (≥70 Gy) was associated with a higher PFS (P = 0.014, 2-year PFS 63.5% vs. 20.8%).

Conclusion

Salvage RT for locally recurrent colorectal cancer can be offered when surgery is impossible. Dose-escalated RT shows a possible benefit in reducing the risk of progression.

Citations

Citations to this article as recorded by  
  • Carbon-ion Radiotherapy for Colorectal Cancer
    Shigeru Yamada, Hirotoshi Takiyama, Yuka Isozaki, Makoto Shinoto, Hirokazu Makishima, Naoyoshi Yamamoto, Hiroshi Tsuji
    Journal of the Anus, Rectum and Colon.2021; 5(2): 113.     CrossRef
  • LncRNA TTN‐AS1/miR‐134‐5p/PAK3 axis regulates the radiosensitivity of human large intestine cancer cells through the P21 pathway and AKT/GSK‐3β/β‐catenin pathway
    Zhenkui Zuo, Shuling Ji, Lulu He, Yage Zhang, Zining Peng, Jiarui Han
    Cell Biology International.2020; 44(11): 2284.     CrossRef
  • A Review on the Special Radiotherapy Techniques of Colorectal Cancer
    Shing Yau Tam, Vincent W. C. Wu
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Comparison of overall survival and quality of life between patients undergoing anal reconstruction and patients undergoing traditional lower abdominal stoma after radical resection
    P. Du, S.-Y. Wang, P.-F. Zheng, J. Mao, H. Hu, Z.-B. Cheng
    Clinical and Translational Oncology.2019; 21(10): 1390.     CrossRef
  • Prospective Observational Study of High-Dose Carbon-Ion Radiotherapy for Pelvic Recurrence of Rectal Cancer (GUNMA 0801)
    Shintaro Shiba, Masahiko Okamoto, Hiroki Kiyohara, Tatsuya Ohno, Takuya Kaminuma, Takayuki Asao, Hitoshi Ojima, Ken Shirabe, Hiroyuki Kuwano, Takashi Nakano
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Effects of varying radiation dosages on MMP1 expression, and MMP1 knockdown on the viability and migration of SW620 cells
    Fang Ju, Na Li, Wenming Wang, Haicheng Yuan
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Dose-Escalated Radiotherapy for the Treatment of Patients With Recurrent Colorectal Cancer
    Hyung Jin Kim, Seong Taek Oh
    Annals of Coloproctology.2016; 32(2): 47.     CrossRef

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP